Palmar plantar erythrodysesthesia epidemiology and demographics: Difference between revisions
(Mahshid) |
|||
Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Palmar Plantar Erythrodysesthesia or Hand-Foot syndrome is a skin-related reaction involving the palms an soles. It commonly occurs due to a reaction to different kinds of chemotherapeutic agent used to treat cancer. The first s. PPE may be classified into grade1, grade 2, grade 3, or grade 4 depending on toxicity rating. The pathophysiologic mechanism of Palmar Plantar Erythrodysesthesia is under active investigation and different mechanisms have been postulated. Histologic biopsy is consistent with toxic reaction<ref name="pmid2061446">{{cite journal| author=Baack BR, Burgdorf WH| title=Chemotherapy-induced acral erythema. | journal=J Am Acad Dermatol | year= 1991 | volume= 24 | issue= 3 | pages= 457-61 | pmid=2061446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2061446 }}</ref>. After extensive studies, it has been determined that Pegylated Liposomal doxorubicin deposits into the eccrine glands which is concentrated in the palms and soles which then causes a drug reaction and development of PPE.<ref name="pmid23969763">{{cite journal| author=Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A et al.| title=Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy. | journal=Skin Pharmacol Physiol | year= 2014 | volume= 27 | issue= 2 | pages= 66-70 | pmid=23969763 | doi=10.1159/000351801 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23969763 }}</ref> Several Different types of Chemotherapeutic agents have been associated with the development of Palmar Plantar Erythrodysesthesia. PPE must be differentiated from Acute Graft Versus Host Response, Tinea manuum and Hand-Foot reaction due to tyrosine kinase inhibitor. | |||
==Epidemiology and demographics== | ==Epidemiology and demographics== |
Revision as of 21:21, 24 September 2018
Palmar plantar erythrodysesthesia Microchapters |
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
---|
Diagnosis |
Treatment |
Palmar plantar erythrodysesthesia epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia epidemiology and demographics |
FDA on Palmar plantar erythrodysesthesia epidemiology and demographics |
CDC on Palmar plantar erythrodysesthesia epidemiology and demographics |
Palmar plantar erythrodysesthesia epidemiology and demographics in the news |
Blogs on Palmar plantar erythrodysesthesia epidemiology and demographics |
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Palmar Plantar Erythrodysesthesia or Hand-Foot syndrome is a skin-related reaction involving the palms an soles. It commonly occurs due to a reaction to different kinds of chemotherapeutic agent used to treat cancer. The first s. PPE may be classified into grade1, grade 2, grade 3, or grade 4 depending on toxicity rating. The pathophysiologic mechanism of Palmar Plantar Erythrodysesthesia is under active investigation and different mechanisms have been postulated. Histologic biopsy is consistent with toxic reaction[1]. After extensive studies, it has been determined that Pegylated Liposomal doxorubicin deposits into the eccrine glands which is concentrated in the palms and soles which then causes a drug reaction and development of PPE.[2] Several Different types of Chemotherapeutic agents have been associated with the development of Palmar Plantar Erythrodysesthesia. PPE must be differentiated from Acute Graft Versus Host Response, Tinea manuum and Hand-Foot reaction due to tyrosine kinase inhibitor.
Epidemiology and demographics
PPE occurs in 6-42% of patients receiving chemotherapy.
References
- ↑ Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
- ↑ Lademann J, Martschick A, Kluschke F, Richter H, Fluhr JW, Patzelt A; et al. (2014). "Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy". Skin Pharmacol Physiol. 27 (2): 66–70. doi:10.1159/000351801. PMID 23969763.